Pentoxifylline for Prevention of Contrast Induced Nephropathy in Chronic Kidney Diseased Patients in Intensive Care Unit

Tanta University70 enrolled

Overview

The aim of this study is to evaluate the effect of pentoxifylline for control of contrast induced nephropathy in chronic kidney diseased patients in intensive care unit.

Contrast-induced acute kidney injury (AKI), which is also known as contrast-induced nephropathy (CIN), is defined as the development of AKI following contrast medium exposure, without an alternative aetiology. Recently, the cyclic nucleotide phosphodiesterase (PDE) has emerged as a promising target for pharmacological intervention against chronic kidney disease (CKD) progression. The nonselective PDE inhibitor pentoxifylline (PTX) is a methyl xanthine derivative. It's an old drug that exhibits prominent anti-inflammatory, anti-proliferative and anti-fibrotic activities both in vitro and in vivo. In addition to its classic indication for intermittent claudication. It has been used primarily to treat patients with peripheral arterial insufficiency.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

Conditions

Pentoxifylline Contrast Induced Nephropathy Chronic Kidney Disease Intensive Care Unit

Interventions

PentoxifyllineDRUG

Patients received hydration (100ml normal saline every hour (2400ml/day) with closed dynamic monitoring of the blood volume and 400 mg oral Pentoxifylline (PTX) three times per day \[dose adjustment according to estimated glomerular filtration rate (eGFR)\] from 24 hr before contrast to 48 hr after contrast procedure.

Normal salineDRUG

Patient received hydration (100ml normal saline every hour (2400ml/day) with closed dynamic monitoring of the blood volume and placebo with same shape and color of Pentoxifylline (PTX) three times per day from 24 hr before contrast to 48 hr after contrast procedure.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age from 18 to 65 years. * Both sexes. * The presence of chronic kidney disease (CKD) is defined according to the National Kidney Foundation-kidney disease Outcomes Quality Initiative guidelines with second or third stage. * Urgent patients expected taking dye in stable cases of cardiac catheterization or pulmonary embolism with Geneva score (4-11). Exclusion Criteria: * Patients with CKD on renal replacement therapy. * Respiratory failure. * Cardiac failure. * Liver failure. * Methylxanthines hypersensitivity.

Locations (1)

Tanta University

Tanta, El-Gharbia, Egypt

Outcomes

Primary Outcomes

Incidence of contrast induced nephropathy

Incidence of contrast induced nephropathy was recorded.

Time frame: 48 hours after contrast procedure.

Secondary Outcomes

Progress of glomerular filtration rate

Progress of glomerular filtration rate after use of pentoxifylline was recorded.

Time frame: 48 hours after contrast procedure.

Lenght of intensive care unit stay

Lenght of intensive care unit stay was recorded.

Time frame: Till the end of procedure (Up to 4 hours)

Need of dialysis

Need of dialysis was recorded.

Time frame: 48 hours after contrast procedure.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.